Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/01/21
Shattuck Labs' (STTK) CEO Taylor Schreiber on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/14/21
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252GlobeNewsWire • 08/11/21
Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021GlobeNewsWire • 08/04/21
Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/10/21
Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences SummitGlobeNewsWire • 04/28/21
Shattuck Labs Announces Participation in Needham's 20th Annual Healthcare ConferenceGlobeNewsWire • 04/06/21
Shattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial OfficerGlobeNewsWire • 03/16/21
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/15/21
Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/11/21
Shattuck Labs Announces Participation in Citi's 2021 Virtual Immuno-Oncology DayGlobeNewsWire • 02/12/21
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewsWire • 11/25/20
Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/13/20
Shattuck Labs Announces Preclinical Proof of Concept Study on Gamma Delta T Cell Engager, GADLEN™, Platform at SITC 2020GlobeNewsWire • 11/11/20